VCYT - ベラサイト （Veracyte Inc.）

The following slide deck was published by Veracyte, Inc.

While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide attention at the moment. Nevertheless, they could yield tremendous profitability if they come through. Another factor that benefits high-risk, high-reward biotech stocks centers on the underlying sector’s permanent relevance. No matter what’s going on with the economy or which bank happens to be failing, scientists will continue marching forward. Chronic diseases don’t wait for economic cycles to pass by and neither does the medical innovation sector. Indeed, when the equities sector crumbled in 2022, the broader healthcare sector generally provided a solid performance . While individual biotechs present volatility risks, the search for viable therapeutics represents a perpetual endeavor. On that note, below are the biotech stocks to add to your portfolio.

Veracyte, Inc. outlined the company’s cash, cash equivalents and short-term investment status in light of the events surrounding Silicon Valley Bank . As of December 31, 2022, the company had… | March 11, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) outlined the company’s cash, cash equivalents and short-term investment status in light of the events surrounding Silicon Valley Bank (SVB). As of December 31, 2022, the company had $178.9 million in cash, cash equivalents and short-term investments. The majority of these assets are not restricted by the Federal Deposit Insurance Corporation’s (FDIC) action to take control of SVB. The company believes its currently acce

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences. Cowen’s 43rd Annual Health Care Conference – Boston, MA Presentation on March 7th at 9:50 a.m. Eastern Time KeyBanc Virtual Life Sciences & MedTech Investor Forum Fireside Chat on March 21st at 3:45 p.m. Eastern Time Live audio webcasts of the company’s pre

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences. Cowen’s 43rd Annual Health Care Conference – Boston, MA Presentation on March 7th at 9:50 a.m. Eastern Time KeyBanc Virtual Life Sciences & MedTech Investor Forum Fireside Chat on March 21st at 3:45 p.m. Eastern Time Live audio webcasts of the company’s pre

Veracyte Inc. (NASDAQ:VCYT) closed Thursday at $23.93 per share, up from $23.90 a day earlier. While Veracyte Inc. has overperformed by 0.13%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VCYT fell by -3.51%, with highs and lows ranging from $32.40 to $14.85, whereas the simple […]

https://www.investing.com/news/pro/veracyte-inc-pt-raised-to-35-at-scotiabank-432SI-3013956

Veracyte Inc. (NASDAQ:VCYT)’s traded shares stood at 1.24 million during the last session, with the company’s beta value hitting 1.44. At the close of trading, the stock’s price was $23.90, to imply an increase of 5.19% or $1.18 in intraday trading. The VCYT share’s 52-week high remains $32.40, putting it -35.56% down since that peak … Veracyte Inc. (NASDAQ: VCYT) Stock Has Dropped -9.19% Over The Month – Is There Room For Growth? Read More »

https://www.investing.com/news/pro/veracyte-inc-pt-raised-to-34-at-needham--company-432SI-3012126

The share price of Veracyte Inc. (NASDAQ:VCYT) rose to $23.77 per share on Wednesday from $22.65. While Veracyte Inc. has overperformed by 4.94%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VCYT fell by -44.08%, with highs and lows ranging from $42.43 to $14.85, whereas the […]

Veracyte Inc. (NASDAQ:VCYT) marked $26.51 per share on Tuesday, up from a previous closing price of $26.43. While Veracyte Inc. has overperformed by 0.30%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VCYT fell by -35.45%, with highs and lows ranging from $45.34 to $14.85, whereas […]

Data published in JCEM demonstrate strong real-world performance of Veracyte’s Afirma GSC in thyroid cancer diagnosis

During the recent session, Veracyte Inc. (NASDAQ:VCYT)’s traded shares were 0.44 million, with the beta value of the company hitting 1.39. At the last check today, the stock’s price was $27.58, reflecting an intraday gain of 2.64% or $0.71. The 52-week high for the VCYT share is $45.58, that puts it down -65.26 from that … The Veracyte Inc. (NASDAQ: VCYT) Stock Dropped 7.65% In A Single Month – Are There Any Hopes For A Gain? Read More »

In Tuesday’s session, Veracyte Inc. (NASDAQ:VCYT) marked $27.25 per share, up from $27.17 in the previous session. While Veracyte Inc. has overperformed by 0.29%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VCYT fell by -27.53%, with highs and lows ranging from $45.58 to $14.85, whereas […]